Avelumab or Hydroxychloroquine With or Without Palbociclib to Eliminate Dormant Breast Cancer
Status:
Recruiting
Trial end date:
2028-05-01
Target enrollment:
Participant gender:
Summary
This clinical trial will assess the safety and early efficacy of Hydroxychloroquine or
Avelumab, with or without Palbociclib, in early-stage ER+ breast cancer patients who are
found to harbor disseminated tumor cells (DTCs) in the bone marrow after definitive surgery
and standard adjuvant therapy.
Phase:
Phase 2
Details
Lead Sponsor:
Abramson Cancer Center of the University of Pennsylvania
Collaborators:
Breast Cancer Research Foundation Johns Hopkins University Pfizer Translational Breast Cancer Research Consortium